Skip to main content
Midas Edge

Curanex Pharmaceuticals Inc

For the period ended Jun 30, 2025. Filed Sep 9, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Sep 9, 2025

CURX$6.21+7.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Changes in Shareholders’ Equity

CHANGES IN SHAREHOLDERS’ EQUITY

Common Stock · Preferred Stock · Common Stock · Additional · Accumulated
Number of Shares · Amount · Number of Shares · Amount · to be issued · Paid in Capital · Deficit · Total
Balance at December 31, 2023600,000$60-$-$200,000$120,973$(260,943)$60,090
Issuance of common stock----150,000--150,000
Net loss------(80,202)(80,202)
Balance at March 31, 2024600,000$60-$-$350,000$120,973$(341,145)$129,888
Issuance of common stock23,400,000$2,340--$(150,000)$777,103-$629,443
Issuance of preferred stock--1,000,000$100---100
Net loss------(44,200)(44,200)
Balance at June 30, 202424,000,000$2,4001,000,000$100$200,000$898,076$(385,345)$715,231
Balance at December 31, 202424,000,000$2,4001,000,000$100$200,000$923,309$(622,449)$503,360
Net loss------(137,583)(137,583)
Balance at March 31, 202524,000,000$2,4001,000,000$100$200,000$923,309$(760,032)$365,777
Net loss------(60,346)(60,346)
Balance at June 30, 202524,000,000$2,4001,000,000$100$200,000$923,309$(820,378)$305,431
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.